Jean Jacques Bienaime Sells 20,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime sold 20,000 shares of the firm’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the transaction, the director now owns 474,994 shares in the company, valued at approximately $43,347,952.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, March 5th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $85.51, for a total transaction of $85,510.00.
• On Tuesday, February 27th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.35, for a total transaction of $90,350.00.
• On Friday, February 9th, Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $88.28, for a total transaction of $1,324,200.00.

BioMarin Pharmaceutical Trading Down 0.7 %

Shares of BMRN opened at $90.87 on Wednesday. BioMarin Pharmaceutical Inc. has a 52-week low of $76.02 and a 52-week high of $100.38. The stock has a market cap of $17.15 billion, a PE ratio of 103.26, a price-to-earnings-growth ratio of 1.76 and a beta of 0.31. The firm’s fifty day moving average is $87.55 and its two-hundred day moving average is $89.10. The company has a quick ratio of 1.57, a current ratio of 2.51 and a debt-to-equity ratio of 0.12.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $646.21 million for the quarter, compared to analysts’ expectations of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.11 EPS. Research analysts forecast that BioMarin Pharmaceutical Inc. will post 1.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Stifel Nicolaus reissued a “buy” rating and set a $101.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Canaccord Genuity Group reissued a “hold” rating and issued a $91.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 29th. Piper Sandler dropped their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Robert W. Baird cut their target price on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $107.61.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds have recently made changes to their positions in the stock. ICA Group Wealth Management LLC acquired a new position in BioMarin Pharmaceutical during the 4th quarter worth about $31,000. KB Financial Partners LLC grew its holdings in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. MayTech Global Investments LLC purchased a new stake in BioMarin Pharmaceutical during the 4th quarter worth approximately $36,000. Dark Forest Capital Management LP acquired a new stake in BioMarin Pharmaceutical during the 1st quarter worth approximately $37,000. Finally, Lindbrook Capital LLC boosted its position in BioMarin Pharmaceutical by 259.8% in the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 278 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.